<DOC>
	<DOCNO>NCT00341939</DOCNO>
	<brief_summary>This study retrospective one , explore hypothesis person 's genotypic makeup may associate clinical response toxic effect drug . Genetic polymorphism , , state able assume different form , drug-metabolizing enzyme , transporter , receptor may affect patient 's response drug therapy . To date , limited study look drug-metabolizing genotype ( genetic makeup ) phenotype ( result genotype 's interaction environment ) . However , often wondered variation drug 's action , , pharmacokinetic effect , come genotype phenotype relationship . Participants enter previous clinical trial National Cancer Institute , approve Central Institutional Review Board , may eligible study . Studies pharmacokinetic analysis perform source patient population . Genotyping experiment perform genomic DNA isolate stored frozen serum . The genotyping result compare pharmacokinetic data clinical outcome . Clinical data consist obtain course principal pharmacokinetic study . The result retrospective analysis provide direct benefit participant .</brief_summary>
	<brief_title>Retrospective Analysis Drug-Metabolizing Genotype Cancer Patients Correlation With Pharmacokinetic Pharmacodynamics Data</brief_title>
	<detailed_description>Background Genetic polymorphisms drug-metabolizing enzyme , transporterss/receptors , transcription factor might affect individual response drug therapy . Inter-individual difference efficacy toxicity cancer chemotherapy especially important give narrow therapeutic index drug . During analysis investigational agent , inter-individual variance pharmacokinetics pharmacodynamics often note . It often wonder variance might part explain genetic difference drug metabolize enzyme , transporter , criticial regulator gene expression . Objectives To good understand genotype-phenotype relationship , additional analysis correlate pharmacokinetic data relevant genotyping . Eligibility All individual previously enrol IRB approve clinical trial National Cancer Institute . Design In retrospective study , association individual pharmacokinetic profile genetic variation drug metabolize enzymes critical regulator gene expression investigate . The hypothesis individual genotypic constitution may associate clinical response and/or toxicity explore .</detailed_description>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>INCLUSION CRITERIA : In retrospective study , cancer patient enter IRB approve clinical trial National Cancer Institute eligible . Studies pharmacokinetic analysis were/are perform source patient population . At time enrollment limit patient pharmacokinetic sample obtain treatment protocol 00C0033 , 00C0080 , 01C0049 , 01C0124 , 01C0215 , 02C0061 , 02C0083 , 02C0130 , 02C0149 , 02C0215 , 02C0218 , 02C0229 , 03C0030 , 03C0157 , 03C0176 , 03C0284 , 04C0132 , 04C0257 , 04C0262 , 04C0273 , 04C0280 , 05C0022 , 05C0049 , 05C0167 , 05C0186 , 06C0083 , 06C0088 , 06C0164 , 06C0221 , 07C0047 , 07C0059 , 07C0106 , 07C0107 , 08C0030 , 08C0074 , 94C0169 , 95C0015 , 97C0135 , 97C0171 , 98C0015 . EXCLUSION CRITERIA : A patient exclude insufficient quantity sample available perform genotyping procedure . This anticipated significance study since methodology require large serum sample .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 27, 2016</verification_date>
	<keyword>Drug Therapy</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Parmacokinetics</keyword>
</DOC>